Unknown PHASE2 INTERVENTIONAL 2-arm NCT03567720

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

A Phase 2 Multi-Cohort, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Pembrolizumab +/- Chemotherapy in Patients With Inoperable Locally Advanced/Metastatic Triple-Negative Breast Cancer

Sponsor: Merck Sharp & Dohme LLC

Conditions Triple Negative Breast Cancer

Interventions Immunopulse Pembrolizumab gemcitabine plus carboplatin nab paclitaxel tavokinogene telseplasmid

Updated 20 times since 2018 Last updated: May 30, 2023 Started: Oct 11, 2018 Primary completion: Apr 30, 2024 Completion: Sep 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Triple Negative Breast Cancer and is currently ongoing. Merck Sharp & Dohme LLC leads this study, which shows 20 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

20 versions recorded

Jun 2025 — Present [monthly]

Unknown PHASE2

Status: Active Not Recruiting → Unknown
Sep 2024 — Jun 2025 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Jul 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jun 2022 — Jul 2023 [monthly]

Recruiting PHASE2

▶ Show 15 earlier versions

May 2022 — Jun 2022 [monthly]

Recruiting PHASE2
Mar 2022 — May 2022 [monthly]

Recruiting PHASE2
Oct 2021 — Mar 2022 [monthly]

Recruiting PHASE2
May 2021 — Oct 2021 [monthly]

Recruiting PHASE2
Mar 2021 — May 2021 [monthly]

Recruiting PHASE2
Jan 2021 — Mar 2021 [monthly]

Recruiting PHASE2
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Active Not Recruiting → Recruiting
Oct 2020 — Nov 2020 [monthly]

Active Not Recruiting PHASE2
Jul 2020 — Oct 2020 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Feb 2020 — Jul 2020 [monthly]

Recruiting PHASE2
Oct 2019 — Feb 2020 [monthly]

Recruiting PHASE2
Sep 2019 — Oct 2019 [monthly]

Recruiting PHASE2
Apr 2019 — Sep 2019 [monthly]

Recruiting PHASE2
Dec 2018 — Apr 2019 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jul 2018 — Dec 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
OncoSec Medical Incorporated

Data source: OncoSec Medical Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Box Hill, Australia , Chicago, United States , Cleveland, United States , Elizabeth Vale, Australia , Fairfax, United States , La Jolla, United States , Palo Alto, United States , Seattle, United States , Tampa, United States and 4 more locations